A manuscript has been published on ORAL Surveillance within the January 27 issue of the New England Journal of Medicine. The manuscript is entitled Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. This peer-reviewed publication reports results from the Oral Rheumatoid Arthritis Trial (ORAL) Surveillance, a randomized, post-marketing requirement study with the primary objective of evaluating the safety of tofacitinib at two doses (5mg twice daily and 10 mg twice daily) compared with a TNF inhibitor in patients with rheumatoid arthritis who were 50 years of age or older and had at least one cardiovascular risk factor. The publication is available here.
The XELJANZ® (tofacitinib) US Prescribing Information can be found here.